Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elien M Doorduijn"'
Autor:
Xiao-Lin Li, Marjolein Sluijter, Elien M Doorduijn, Shubha P Kale, Harris McFerrin, Yong-Yu Liu, Yan Li, Madhusoodanan Mottamal, Xin Yao, Fengkun Du, Baihan Gu, Kim Hoang, Yen H Nguyen, Nichelle Taylor, Chelsea R Stephens, Thorbald van Hall, Qian-Jin Zhang
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e108192 (2014)
The association of B7-1/CD28 between antigen presenting cells (APCs) and T-cells provides a second signal to proliferate and activate T-cell immunity at the induction phase. Many reports indicate that tumor cells transfected with B7-1 induced augment
Externí odkaz:
https://doaj.org/article/f19ef3458ca444f3bfe66781882d6c97
Autor:
Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp, Ramon Arens, Saskia Maas, Serenella Silvestri, Daniela C. Salvatori, Marjolein Sluijter, Elien M. Doorduijn
T cell phenotype after treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed60da620b4b5b7637c656af2898a66
https://doi.org/10.1158/2326-6066.22539304
https://doi.org/10.1158/2326-6066.22539304
Autor:
Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp, Ramon Arens, Saskia Maas, Serenella Silvestri, Daniela C. Salvatori, Marjolein Sluijter, Elien M. Doorduijn
Legends of supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6ddee11c469f5e8ccc496666f6214d3
https://doi.org/10.1158/2326-6066.22539301
https://doi.org/10.1158/2326-6066.22539301
Autor:
Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp, Ramon Arens, Saskia Maas, Serenella Silvestri, Daniela C. Salvatori, Marjolein Sluijter, Elien M. Doorduijn
One of the next challenges in cancer immunotherapy is the resistance of tumors to T-cell–based treatments through loss of MHC class I. Here, we show that under these circumstances, the Toll-like receptor (TLR)-7/8 ligand imiquimod, but not the TLR3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef1d8a3fb684b57b044f7641b1508fc6
https://doi.org/10.1158/2326-6066.c.6549049.v1
https://doi.org/10.1158/2326-6066.c.6549049.v1
Autor:
Elien M. Doorduijn, Marjolein Sluijter, Koen A. Marijt, Bianca J. Querido, Sjoerd H. van der Burg, Thorbald van Hall
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Cancers frequently evade immune-recognition by lowering peptide:MHC-I complexes on their cell surface. Limited peptide supply due to TAP-deficiency results in such MHC-Ilow immune-escape variants. Previously, we reported on a category of TAP-independ
Externí odkaz:
https://doaj.org/article/c2e0ac7b3d434c328ea6ff06848bbc5a
Autor:
Cara Haymaker, Jason Roszik, Jie Qing Chen, Jahan Khalili, Zhe Wang, Nikunj Satani, Rina M. Mbofung, Laurence J.N. Cooper, Marie-Andree Forget, Willem W. Overwijk, Chunyu Xu, Leila Williams, Weiyi Peng, Chengwen Liu, Deborah A. Silverman, Simone Punt, Sourindra Maiti, Florian L. Muller, Elien M Doorduijn, Chantale Bernatchez, Trang N. Tieu, Ana Lucia Dominguez, Soraya Zorro Manrique, Patrick Hwu, Shruti Malu, Emily Ashkin, Jodi A. McKenzie, Rodabe N. Amaria, Timothy P. Heffernan
Publikováno v:
Cancer Immunology, Immunotherapy
Although immunotherapy has achieved impressive durable clinical responses, many cancers respond only temporarily or not at all to immunotherapy. To find novel, targetable mechanisms of resistance to immunotherapy, patient-derived melanoma cell lines
Publikováno v:
Molecular Immunology, 113, 43-49
T-cell based immunotherapies through checkpoint blockade or adoptive transfer are effective treatments for a wide range of cancers like melanomas and lung carcinomas that harbor a high mutational load. The HLA class I and class II (HLA-I and HLA-II)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18883092ff25cdfce8744025ce3c5451
https://doi.org/10.1016/j.molimm.2018.03.029
https://doi.org/10.1016/j.molimm.2018.03.029
Autor:
Adnane Achour, Renhua Sun, T. van Hall, Tatyana Sandalova, Marjolein Sluijter, Elien M. Doorduijn, A. Talyzina, I. Hafstrand, Sara Pellegrino, Adil Doganay Duru
Publikováno v:
The Journal of Immunology. 200:2860-2868
Human cancers frequently display defects in Ag processing and presentation allowing for immune evasion, and they therefore constitute a significant challenge for T cell–based immunotherapy. We have previously demonstrated that the antigenicity of t
Autor:
Ailem Rabasa, Thorbald van Hall, Francesca D’Eramo, Eli Gilboa, Tal Gefen, Brett Schrand, Koen A. Marijt, Alexey Berezhnoy, Vikas Dudeja, Greta Garrido, Shrey Modi, Agata Levay, Elien M. Doorduijn
Publikováno v:
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications, 10
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications, 10
Neoantigen burden is a major determinant of tumor immunogenicity, underscored by recent clinical experience with checkpoint blockade therapy. Yet the majority of patients do not express, or express too few, neoantigens, and hence are less responsive
Autor:
Bianca Querido, Marjolein Sluijter, Elien M. Doorduijn, Koen A. Marijt, Sjoerd H. van der Burg, Thorbald van Hall
Publikováno v:
OncoImmunology
OncoImmunology, Vol 7, Iss 3 (2018)
OncoImmunology, 7(3)
Oncoimmunology
OncoImmunology, Vol 7, Iss 3 (2018)
OncoImmunology, 7(3)
Oncoimmunology
Cancers frequently evade immune-recognition by lowering peptide:MHC-I complexes on their cell surface. Limited peptide supply due to TAP-deficiency results in such MHC-Ilow immune-escape variants. Previously, we reported on a category of TAP-independ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf44fb1c1984dc49c2a0c034c086f1e
https://doi.org/10.1080/2162402x.2017.1382793
https://doi.org/10.1080/2162402x.2017.1382793